A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis.
Systemic sclerosis
digital ulcers
phototherapy
scleroderma
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
pubmed:
5
6
2018
medline:
14
6
2019
entrez:
5
6
2018
Statut:
ppublish
Résumé
Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed. Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy. A custom-built device comprising infrared (850 nm), red (660 nm), and violet (405 nm) LEDs was utilized. DUs were irradiated with 10 J/cm In all, 14 DUs in eight patients received a total of 46 light exposures, with no safety concerns. All patients considered LTTT 'took just the right amount of time' and was 'feasible', with a low associated mean pain VAS of 1.6 (SD: 5.2). Patient and clinician global DC VAS improved during the study (mean change: -7.1 and -5.2, respectively, both p < .001). DU perfusion significantly increased post-irradiation. LTTT for DUs is safe, feasible, and well tolerated. There was an early tentative suggestion of treatment efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed.
OBJECTIVES
OBJECTIVE
Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy.
METHODS
METHODS
A custom-built device comprising infrared (850 nm), red (660 nm), and violet (405 nm) LEDs was utilized. DUs were irradiated with 10 J/cm
RESULTS
RESULTS
In all, 14 DUs in eight patients received a total of 46 light exposures, with no safety concerns. All patients considered LTTT 'took just the right amount of time' and was 'feasible', with a low associated mean pain VAS of 1.6 (SD: 5.2). Patient and clinician global DC VAS improved during the study (mean change: -7.1 and -5.2, respectively, both p < .001). DU perfusion significantly increased post-irradiation.
CONCLUSIONS
CONCLUSIONS
LTTT for DUs is safe, feasible, and well tolerated. There was an early tentative suggestion of treatment efficacy.
Identifiants
pubmed: 29862855
doi: 10.1080/09546634.2018.1484875
pmc: PMC6484448
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-257Subventions
Organisme : Versus Arthritis
ID : 20482
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 19465
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 20482
Pays : United Kingdom
Références
Ann Intern Med. 2000 Mar 21;132(6):425-34
pubmed: 10733441
Cell Mol Biol (Noisy-le-grand). 2000 Nov;46(7):1297-303
pubmed: 11075959
Photodermatol Photoimmunol Photomed. 2001 Feb;17(1):32-8
pubmed: 11169174
J Wound Care. 2003 Jan;12(1):37-40
pubmed: 12572235
Photomed Laser Surg. 2006 Dec;24(6):684-8
pubmed: 17199466
Mol Med. 2007 Jan-Feb;13(1-2):22-9
pubmed: 17515954
J Rheumatol. 2007 Dec;34(12):2423-30
pubmed: 17985402
Vojnosanit Pregl. 2008 Dec;65(12):906-12
pubmed: 19160985
Photomed Laser Surg. 2009 Feb;27(1):111-8
pubmed: 19196110
J Rheumatol. 2009 Jul;36(7):1470-6
pubmed: 19487271
Lasers Surg Med. 2009 Aug;41(6):433-41
pubmed: 19588536
Arthritis Care Res (Hoboken). 2011 Jan;63(1):142-9
pubmed: 20740608
Ann Rheum Dis. 2011 Jan;70(1):32-8
pubmed: 20805294
Arthritis Care Res (Hoboken). 2011 Feb;63(2):277-85
pubmed: 20824802
Photomed Laser Surg. 2011 Feb;29(2):109-14
pubmed: 21214368
Photomed Laser Surg. 2011 Jun;29(6):399-404
pubmed: 21214497
Arthritis Care Res (Hoboken). 2012 Feb;64(2):295-7
pubmed: 22012860
Ann Biomed Eng. 2012 Feb;40(2):516-33
pubmed: 22045511
Injury. 2011 Sep;42(9):917-21
pubmed: 22081819
Ann Rheum Dis. 2012 May;71(5):718-21
pubmed: 22247218
Br J Dermatol. 2013 Mar;168(3):617-24
pubmed: 23066973
Scand J Rheumatol. 2013;42(6):483-6
pubmed: 23826651
Acta Derm Venereol. 2014 Mar;94(2):250-1
pubmed: 23975450
Semin Cutan Med Surg. 2013 Mar;32(1):41-52
pubmed: 24049929
Indian J Surg. 2012 Oct;74(5):359-63
pubmed: 24082586
Evid Based Complement Alternat Med. 2013;2013:960240
pubmed: 24159357
J Rheumatol. 2014 Jul;41(7):1317-23
pubmed: 24931950
Lasers Surg Med. 2015 Feb;47(2):210-5
pubmed: 25655579
Ann Rheum Dis. 2016 Jun;75(6):1009-15
pubmed: 25995322
Microvasc Res. 2015 Sep;101:82-5
pubmed: 26142117
Ann Rheum Dis. 2016 Oct;75(10):1770-6
pubmed: 26612339
Rheumatology (Oxford). 2017 Jan;56(1):14-25
pubmed: 27094599
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):100-105
pubmed: 27749241
Free Radic Biol Med. 2017 Jul;108:300-310
pubmed: 28315451
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):218-219
pubmed: 28598784
Photodermatol Photoimmunol Photomed. 2017 Nov;33(6):296-305
pubmed: 28703365
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Ann Intern Med. 1994 Feb 1;120(3):199-206
pubmed: 7506013
Dermatol Surg. 1998 Dec;24(12):1383-6
pubmed: 9865208